MicroRNAs in Animal Models of HCC
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality. Molecular heterogeneity and absence of biomarkers for patient allocation to the best therapeutic option contribute to poor prognosis of advanced stages. Aberrant microRNA (miRNA) expression is associated with HCC...
Gespeichert in:
| Veröffentlicht in: | Cancers 2019-12, Vol.11 (12), p.1906 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | 1906 |
| container_title | Cancers |
| container_volume | 11 |
| creator | Fornari, Francesca Gramantieri, Laura Callegari, Elisa Shankaraiah, Ram C Piscaglia, Fabio Negrini, Massimo Giovannini, Catia |
| description | Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality. Molecular heterogeneity and absence of biomarkers for patient allocation to the best therapeutic option contribute to poor prognosis of advanced stages. Aberrant microRNA (miRNA) expression is associated with HCC development and progression and influences drug resistance. Therefore, miRNAs have been assayed as putative biomarkers and therapeutic targets. MiRNA-based therapeutic approaches demonstrated safety profiles and antitumor efficacy in HCC animal models; nevertheless, caution should be used when transferring preclinical findings to the clinics, due to possible molecular inconsistency between animal models and the heterogeneous pattern of the human disease. In this context, models with defined genetic and molecular backgrounds might help to identify novel therapeutic options for specific HCC subgroups. In this review, we describe rodent models of HCC, emphasizing their representativeness with the human pathology and their usefulness as preclinical tools for assessing miRNA-based therapeutic strategies. |
| doi_str_mv | 10.3390/cancers11121906 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6966618</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2322742019</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-b521ff3ff4e6b862a4e71010a7a744c952ee191305bea86fb11d6f10d108990f3</originalsourceid><addsrcrecordid>eNpdUcFKAzEQDaLYUnv2JitevKzNJNlkcxHKUq3QKoieQ3Y30S3bTU26gn_vltZSO5cZmDePN-8hdAn4jlKJR4VuCuMDABCQmJ-gPsGCxJxLdnow99AwhAXuilIQXJyjHoUUJ5xCH13Pq8K71-dxiKomGjfVUtfR3JWmDpGz0TTLLtCZ1XUww10foPeHyVs2jWcvj0_ZeBYXjMA6zhMC1lJrmeF5yolmRgAGrIUWjBUyIcaABIqT3OiU2xyg5BZwCTiVEls6QPdb3lWbL01ZmGbtda1WvpPkf5TTlfq_aapP9eG-FZecc0g7gtsdgXdfrQlrtaxCYepaN8a1QRFKiGAEg-ygN0fQhWt9072nSMJEQqhMNoSjLapzKARv7F4MYLVJQB0l0F1cHf6wx__5TX8B5cB_tA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2547523958</pqid></control><display><type>article</type><title>MicroRNAs in Animal Models of HCC</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Fornari, Francesca ; Gramantieri, Laura ; Callegari, Elisa ; Shankaraiah, Ram C ; Piscaglia, Fabio ; Negrini, Massimo ; Giovannini, Catia</creator><creatorcontrib>Fornari, Francesca ; Gramantieri, Laura ; Callegari, Elisa ; Shankaraiah, Ram C ; Piscaglia, Fabio ; Negrini, Massimo ; Giovannini, Catia</creatorcontrib><description>Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality. Molecular heterogeneity and absence of biomarkers for patient allocation to the best therapeutic option contribute to poor prognosis of advanced stages. Aberrant microRNA (miRNA) expression is associated with HCC development and progression and influences drug resistance. Therefore, miRNAs have been assayed as putative biomarkers and therapeutic targets. MiRNA-based therapeutic approaches demonstrated safety profiles and antitumor efficacy in HCC animal models; nevertheless, caution should be used when transferring preclinical findings to the clinics, due to possible molecular inconsistency between animal models and the heterogeneous pattern of the human disease. In this context, models with defined genetic and molecular backgrounds might help to identify novel therapeutic options for specific HCC subgroups. In this review, we describe rodent models of HCC, emphasizing their representativeness with the human pathology and their usefulness as preclinical tools for assessing miRNA-based therapeutic strategies.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers11121906</identifier><identifier>PMID: 31805631</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Animal models ; Antitumor activity ; Binding sites ; Biomarkers ; Biosynthesis ; Cancer ; Cholesterol ; Diet ; Drug resistance ; Epigenetics ; Gene expression ; Genotype & phenotype ; Hepatitis ; Hepatocellular carcinoma ; Lipids ; Liver diseases ; Medical prognosis ; Medical research ; Metabolism ; MicroRNAs ; miRNA ; Molecular modelling ; Physiology ; Review ; Therapeutic targets</subject><ispartof>Cancers, 2019-12, Vol.11 (12), p.1906</ispartof><rights>2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-b521ff3ff4e6b862a4e71010a7a744c952ee191305bea86fb11d6f10d108990f3</citedby><cites>FETCH-LOGICAL-c421t-b521ff3ff4e6b862a4e71010a7a744c952ee191305bea86fb11d6f10d108990f3</cites><orcidid>0000-0001-9824-0560 ; 0000-0003-1904-1577 ; 0000-0001-8264-1845 ; 0000-0002-4302-4411</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966618/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966618/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31805631$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fornari, Francesca</creatorcontrib><creatorcontrib>Gramantieri, Laura</creatorcontrib><creatorcontrib>Callegari, Elisa</creatorcontrib><creatorcontrib>Shankaraiah, Ram C</creatorcontrib><creatorcontrib>Piscaglia, Fabio</creatorcontrib><creatorcontrib>Negrini, Massimo</creatorcontrib><creatorcontrib>Giovannini, Catia</creatorcontrib><title>MicroRNAs in Animal Models of HCC</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality. Molecular heterogeneity and absence of biomarkers for patient allocation to the best therapeutic option contribute to poor prognosis of advanced stages. Aberrant microRNA (miRNA) expression is associated with HCC development and progression and influences drug resistance. Therefore, miRNAs have been assayed as putative biomarkers and therapeutic targets. MiRNA-based therapeutic approaches demonstrated safety profiles and antitumor efficacy in HCC animal models; nevertheless, caution should be used when transferring preclinical findings to the clinics, due to possible molecular inconsistency between animal models and the heterogeneous pattern of the human disease. In this context, models with defined genetic and molecular backgrounds might help to identify novel therapeutic options for specific HCC subgroups. In this review, we describe rodent models of HCC, emphasizing their representativeness with the human pathology and their usefulness as preclinical tools for assessing miRNA-based therapeutic strategies.</description><subject>Animal models</subject><subject>Antitumor activity</subject><subject>Binding sites</subject><subject>Biomarkers</subject><subject>Biosynthesis</subject><subject>Cancer</subject><subject>Cholesterol</subject><subject>Diet</subject><subject>Drug resistance</subject><subject>Epigenetics</subject><subject>Gene expression</subject><subject>Genotype & phenotype</subject><subject>Hepatitis</subject><subject>Hepatocellular carcinoma</subject><subject>Lipids</subject><subject>Liver diseases</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metabolism</subject><subject>MicroRNAs</subject><subject>miRNA</subject><subject>Molecular modelling</subject><subject>Physiology</subject><subject>Review</subject><subject>Therapeutic targets</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdUcFKAzEQDaLYUnv2JitevKzNJNlkcxHKUq3QKoieQ3Y30S3bTU26gn_vltZSO5cZmDePN-8hdAn4jlKJR4VuCuMDABCQmJ-gPsGCxJxLdnow99AwhAXuilIQXJyjHoUUJ5xCH13Pq8K71-dxiKomGjfVUtfR3JWmDpGz0TTLLtCZ1XUww10foPeHyVs2jWcvj0_ZeBYXjMA6zhMC1lJrmeF5yolmRgAGrIUWjBUyIcaABIqT3OiU2xyg5BZwCTiVEls6QPdb3lWbL01ZmGbtda1WvpPkf5TTlfq_aapP9eG-FZecc0g7gtsdgXdfrQlrtaxCYepaN8a1QRFKiGAEg-ygN0fQhWt9072nSMJEQqhMNoSjLapzKARv7F4MYLVJQB0l0F1cHf6wx__5TX8B5cB_tA</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Fornari, Francesca</creator><creator>Gramantieri, Laura</creator><creator>Callegari, Elisa</creator><creator>Shankaraiah, Ram C</creator><creator>Piscaglia, Fabio</creator><creator>Negrini, Massimo</creator><creator>Giovannini, Catia</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9824-0560</orcidid><orcidid>https://orcid.org/0000-0003-1904-1577</orcidid><orcidid>https://orcid.org/0000-0001-8264-1845</orcidid><orcidid>https://orcid.org/0000-0002-4302-4411</orcidid></search><sort><creationdate>20191201</creationdate><title>MicroRNAs in Animal Models of HCC</title><author>Fornari, Francesca ; Gramantieri, Laura ; Callegari, Elisa ; Shankaraiah, Ram C ; Piscaglia, Fabio ; Negrini, Massimo ; Giovannini, Catia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-b521ff3ff4e6b862a4e71010a7a744c952ee191305bea86fb11d6f10d108990f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animal models</topic><topic>Antitumor activity</topic><topic>Binding sites</topic><topic>Biomarkers</topic><topic>Biosynthesis</topic><topic>Cancer</topic><topic>Cholesterol</topic><topic>Diet</topic><topic>Drug resistance</topic><topic>Epigenetics</topic><topic>Gene expression</topic><topic>Genotype & phenotype</topic><topic>Hepatitis</topic><topic>Hepatocellular carcinoma</topic><topic>Lipids</topic><topic>Liver diseases</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metabolism</topic><topic>MicroRNAs</topic><topic>miRNA</topic><topic>Molecular modelling</topic><topic>Physiology</topic><topic>Review</topic><topic>Therapeutic targets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fornari, Francesca</creatorcontrib><creatorcontrib>Gramantieri, Laura</creatorcontrib><creatorcontrib>Callegari, Elisa</creatorcontrib><creatorcontrib>Shankaraiah, Ram C</creatorcontrib><creatorcontrib>Piscaglia, Fabio</creatorcontrib><creatorcontrib>Negrini, Massimo</creatorcontrib><creatorcontrib>Giovannini, Catia</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fornari, Francesca</au><au>Gramantieri, Laura</au><au>Callegari, Elisa</au><au>Shankaraiah, Ram C</au><au>Piscaglia, Fabio</au><au>Negrini, Massimo</au><au>Giovannini, Catia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MicroRNAs in Animal Models of HCC</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2019-12-01</date><risdate>2019</risdate><volume>11</volume><issue>12</issue><spage>1906</spage><pages>1906-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality. Molecular heterogeneity and absence of biomarkers for patient allocation to the best therapeutic option contribute to poor prognosis of advanced stages. Aberrant microRNA (miRNA) expression is associated with HCC development and progression and influences drug resistance. Therefore, miRNAs have been assayed as putative biomarkers and therapeutic targets. MiRNA-based therapeutic approaches demonstrated safety profiles and antitumor efficacy in HCC animal models; nevertheless, caution should be used when transferring preclinical findings to the clinics, due to possible molecular inconsistency between animal models and the heterogeneous pattern of the human disease. In this context, models with defined genetic and molecular backgrounds might help to identify novel therapeutic options for specific HCC subgroups. In this review, we describe rodent models of HCC, emphasizing their representativeness with the human pathology and their usefulness as preclinical tools for assessing miRNA-based therapeutic strategies.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>31805631</pmid><doi>10.3390/cancers11121906</doi><orcidid>https://orcid.org/0000-0001-9824-0560</orcidid><orcidid>https://orcid.org/0000-0003-1904-1577</orcidid><orcidid>https://orcid.org/0000-0001-8264-1845</orcidid><orcidid>https://orcid.org/0000-0002-4302-4411</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2019-12, Vol.11 (12), p.1906 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6966618 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Animal models Antitumor activity Binding sites Biomarkers Biosynthesis Cancer Cholesterol Diet Drug resistance Epigenetics Gene expression Genotype & phenotype Hepatitis Hepatocellular carcinoma Lipids Liver diseases Medical prognosis Medical research Metabolism MicroRNAs miRNA Molecular modelling Physiology Review Therapeutic targets |
| title | MicroRNAs in Animal Models of HCC |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T20%3A59%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MicroRNAs%20in%20Animal%20Models%20of%20HCC&rft.jtitle=Cancers&rft.au=Fornari,%20Francesca&rft.date=2019-12-01&rft.volume=11&rft.issue=12&rft.spage=1906&rft.pages=1906-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers11121906&rft_dat=%3Cproquest_pubme%3E2322742019%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2547523958&rft_id=info:pmid/31805631&rfr_iscdi=true |